Alaunos Therapeutics Inc

Alaunos Therapeutics Inc. a clinical-stage oncology-focused cell therapy company develops adoptive TCR engineered T-cell therapies. It develops TCR Library which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS TP53 and EGFR from its TCR library for the treatment of non-small cell lung colorectal endometrial pancreatic ovarian and bile duct cancers; hunTR a human neoantigen T-cell receptor engine. The company has a license agreement with PGEN Therapeutics Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology Inc. and changed its name to Alaunos Therapeutics Inc. in January 2022. Alaunos Therapeutics Inc. was founded in 2003 and is headquartered in Houston Texas.